BioCentury | Apr 26, 2019
Financial News
Nanjing Leads closes series A for immuno-oncology programs
...Ventures and New Vision Ventures participated, along with new investors Huafang Capital and Huaige Capital. Nanjing Leads Biolabs Co. Ltd....
...million) in total, including angel and series pre-A rounds. Hongjiang Li, Staff Writer Lymphocyte-activation gene 3 (LAG3) (CD223) Nanjing Leads Biolabs Co. Ltd....
...million) in total, including angel and series pre-A rounds. Hongjiang Li, Staff Writer Lymphocyte-activation gene 3 (LAG3) (CD223) Nanjing Leads Biolabs Co. Ltd....
